DM199
Cross-source consensus on DM199 from 1 sources and 4 claims.
1 sources · 4 claims
Benefits
Dosage & preparation
Interactions
Where it comes from
Highlighted claims
- DM199 is a purified recombinant formulation of human tissue kallikrein-1 with two stability-related substitutions outside the active site. — Safety and potential efficacy of DM199, a tissue kallikrein-1 analogue, for treating pre-eclampsia and fetal growth restriction: study protocol for a South African, hospital-based phase I/II open-label trial
- The trial uses IV DM199 as a loading dose and SC DM199 for sustained effect over three days. — Safety and potential efficacy of DM199, a tissue kallikrein-1 analogue, for treating pre-eclampsia and fetal growth restriction: study protocol for a South African, hospital-based phase I/II open-label trial
- DM199 should not be started within 24 hours of ACE inhibitor use because ACE inhibition may excessively potentiate bradykinin signalling and cause severe hypotension. — Safety and potential efficacy of DM199, a tissue kallikrein-1 analogue, for treating pre-eclampsia and fetal growth restriction: study protocol for a South African, hospital-based phase I/II open-label trial
- DM199 therapeutic doses do not lower blood pressure in normotensive individuals according to prior non-pregnant data. — Safety and potential efficacy of DM199, a tissue kallikrein-1 analogue, for treating pre-eclampsia and fetal growth restriction: study protocol for a South African, hospital-based phase I/II open-label trial